Bradley Titus
Cardiovascular Disease · Coos Bay, ORNPI 1962494757
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,107 of the $7,305 with a category attached, or 69.9%. 35 manufacturers reported payments, led by Angiodynamics, Inc. at 29.9% of the total. Reporting peaked in 2022 at $2,306 and has fallen 91.7% since, to $191 in 2024.
Across 375 payments — averaging $19.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$2K
- Johnson & Johnson$602
- Novartis$597
- Amgen$448
- Actelion Pharmaceuticals US, Inc.$365
- Amarin Pharma, Inc.$282
- plus $3K from 29 others
What the payments were for
- Food & beverage$5,10770%
- Education$2784%
- Other$1,92026%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 4 | $2,181 |
| Johnson & Johnson | 44 | $602 |
| Novartis | 90 | $597 |
| Amgen | 31 | $448 |
| Actelion Pharmaceuticals US, Inc. | 21 | $365 |
| Amarin Pharma, Inc. | 19 | $282 |
| Esperion Therapeutics, Inc. | 16 | $278 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $278 |
| Alnylam Pharmaceuticals Inc. | 11 | $249 |
| Bayer | 15 | $229 |
| Veryan Medical Incorporated | 1 | $213 |
| Merck | 10 | $168 |
| AstraZeneca | 13 | $168 |
| Pfizer | 9 | $146 |
| E.r. Squibb & Sons, L.L.C. | 10 | $143 |
| Abbott | 8 | $132 |
| Sanofi-aventis U.S. LLC | 8 | $131 |
| Daiichi Sankyo Inc. | 5 | $108 |
| Irhythm Technologies, Inc. | 5 | $97 |
| United Therapeutics Corporation | 5 | $73 |
| Akcea Therapeutics, Inc. | 3 | $62 |
| Chiesi USA, Inc. | 4 | $62 |
| Arbor Pharmaceuticals, Inc. | 2 | $40 |
| Azurity Pharmaceuticals, Inc. | 2 | $38 |
| Bardy Diagnostics, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $30 |
| Lantheus Medical Imaging, Inc. | 1 | $22 |
| Cvrx, Inc. | 2 | $22 |
| Preventice Services, LLC | 1 | $21 |
| Biotronik Inc. | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| G Medical Diagnostic Services, Inc. | 1 | $16 |
| Amryt Pharma Holdings Ltd | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $14 |
| Philips North America LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaCure 1470 Pro$2,167
- BioMimics$213
How this compares
$7,305 in reported general payments places this provider in the 80th percentile of 198 cardiovascular disease providers in Oregon.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 143 | $139,776 |
| EntrestoSacubitril/Valsartan | 55 | $50,042 |
| Repatha SureclickEvolocumab | 13 | $16,804 |
| XareltoRivaroxaban | 18 | $14,741 |
| BrilintaTicagrelor | 18 | $9,451 |
| EdarbiAzilsartan Medoxomil | 13 | $5,048 |
| ClopidogrelClopidogrel Bisulfate | 127 | $1,809 |
| Bumetanide | 27 | $1,306 |
| Metoprolol Succinate | 75 | $1,186 |
| Atorvastatin Calcium | 85 | $1,059 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 28 | $933 |
| Flecainide Acetate | 15 | $851 |
| Olmesartan Medoxomil | 32 | $849 |
| Midodrine Hcl | 27 | $827 |
| Ezetimibe | 23 | $739 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $146 | $139,776143 claims |
| NovartisEntresto | $597 | $50,04255 claims |
| Johnson & JohnsonXarelto | $602 | $14,74118 claims |
| AstraZenecaBrilinta | $168 | $9,45118 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $40 | $5,04813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 198 cardiovascular disease providers in Oregon.
Other cardiovascular disease in Coos Bay
- Firas ZahrPortland$810K
- Kathy GreweHood River$376K
- Scott ChadderdonPortland$282K
- Ahmad MasriPortland$227K
- Ashwat DhillonCorvallis$156K
- Stephen HeitnerPortland$105K
- Ian RiddockBend$81K
- Abhushan PoudyalPortland$54K
- Douglas DawleyPortland$45K
- Kishor KhanalPortland$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.